At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model.
In Brief
A Phase 2 clinical trial evaluating EDP-938 Dose 1, EDP-938 Dose 2, and 3 other interventions for RSV Infection. Completed, enrolled 179 participants across 1 site.
Detailed Summary
A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.
Study Details
Timeline
Interventions
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days
Oral suspension for 5 days